Human Papillomavirus Infections - Pipeline Review, H1 2014 @ http://www.researchmoz.us/human-papillomavirus-infections-pipeline-review-h1-2014-report.html This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

1. Human Papillomavirus Infections - Pipeline Review, H1 2014
Human Papillomavirus Infections - Pipeline Review, H1 2014
Summary
Global Markets Directs, Human Papillomavirus Infections - Pipeline Review, H1 2014, provides an overview of the Human Papillomavirus Infectionss
therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Human Papillomavirus Infections, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates,
and featured news and press releases. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections and special
features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Human Papillomavirus Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
- The report reviews key players involved in the therapeutics development for Human Papillomavirus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Human Papillomavirus Infections products under development by companies and universities/research institutes based on information derived
from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Human Papillomavirus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand
business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
table Of Contents 2
list Of Tables 7
list Of Figures 8
introduction 9
global Markets Direct Report Coverage 9
human Papillomavirus Infections Overview 10
therapeutics Development 11
pipeline Products For Human Papillomavirus Infections - Overview 11
pipeline Products For Human Papillomavirus Infections - Comparative Analysis 12
human Papillomavirus Infections - Therapeutics Under Development By Companies 13
human Papillomavirus Infections - Therapeutics Under Investigation By Universities/institutes 16
human Papillomavirus Infections - Pipeline Products Glance 18
late Stage Products 18
Human Papillomavirus Infections - Pipeline Review, H1 2014

2. clinical Stage Products 19
early Stage Products 20
unknown Stage Products 21
human Papillomavirus Infections - Products Under Development By Companies 22
human Papillomavirus Infections - Products Under Investigation By Universities/institutes 25
human Papillomavirus Infections - Companies Involved In Therapeutics Development 26
merck & Co., Inc. 26
takeda Pharmaceutical Company Limited 27
medigene Ag 28
chong Kun Dang Pharmaceutical Corp. 29
crucell N.v. 30
starpharma Holdings Limited 31
bharat Biotech International Limited 32
flugen, Inc. 33
biomas Ltd. 34
apovax, Inc. 35
genticel 36
genetic Immunity, Inc 37
vaxart, Inc. 38
irx Therapeutics, Inc. 39
selecta Biosciences, Inc. 40
spider Biotech S.r.l. 41
eyegene, Inc. 42
indian Immunologicals Limited 43
beijing Minhai Biotechnology Co., Ltd 44
coridon Pty Ltd 45
chongqing Zhifei Biological Products Co., Ltd. 46
redbiotec Ag 47
agilvax, Inc. 48
human Papillomavirus Infections - Therapeutics Assessment 49
assessment By Monotherapy Products 49
assessment By Target 50
assessment By Mechanism Of Action 53
assessment By Route Of Administration 56
assessment By Molecule Type 58
drug Profiles 61
v-503 - Drug Profile 61
product Description 61
mechanism Of Action 61
r&d Progress 61
v-503 - Drug Profile 63
product Description 63
mechanism Of Action 63
r&d Progress 63
procervix - Drug Profile 65
product Description 65
mechanism Of Action 65
r&d Progress 65
as-101 - Drug Profile 66
product Description 66
mechanism Of Action 66
r&d Progress 66
astodrimer - Drug Profile 68
product Description 68
mechanism Of Action 68
r&d Progress 68
celecoxib - Drug Profile 70
product Description 70
mechanism Of Action 70
r&d Progress 70
av2-dm - Drug Profile 71
product Description 71
mechanism Of Action 71
r&d Progress 71
eg-hpv - Drug Profile 72
product Description 72
mechanism Of Action 72
r&d Progress 72
Human Papillomavirus Infections - Pipeline Review, H1 2014

3. first Generation Bivalent Hpv Vaccine - Drug Profile 73
product Description 73
mechanism Of Action 73
r&d Progress 73
ckd-12201 - Drug Profile 74
product Description 74
mechanism Of Action 74
r&d Progress 74
apovax-104-hpv - Drug Profile 75
product Description 75
mechanism Of Action 75
r&d Progress 75
irx-3 - Drug Profile 76
product Description 76
mechanism Of Action 76
r&d Progress 76
human Papillomavirus Vaccine - Drug Profile 77
product Description 77
mechanism Of Action 77
r&d Progress 77
rbt-201 - Drug Profile 78
product Description 78
mechanism Of Action 78
r&d Progress 78
vaccine For Hpv - Drug Profile 79
product Description 79
mechanism Of Action 79
r&d Progress 79
aavlp Program - Drug Profile 80
product Description 80
mechanism Of Action 80
r&d Progress 80
human Papillomavirus Vaccine - Drug Profile 81
product Description 81
mechanism Of Action 81
r&d Progress 81
ax-03 - Drug Profile 82
product Description 82
mechanism Of Action 82
r&d Progress 82
sb-105 - Drug Profile 83
product Description 83
mechanism Of Action 83
r&d Progress 83
human Papilloma Virus Vaccine - Drug Profile 84
product Description 84
mechanism Of Action 84
r&d Progress 84
kanda Human Papillomavirus Vaccine - Drug Profile 85
product Description 85
mechanism Of Action 85
r&d Progress 85
4-valent Human Papillomavirus Vaccine - Drug Profile 86
product Description 86
mechanism Of Action 86
r&d Progress 86
human Papilloma Virus Vaccine - Drug Profile 87
product Description 87
mechanism Of Action 87
r&d Progress 87
rkp-00156 - Drug Profile 88
product Description 88
mechanism Of Action 88
r&d Progress 88
human Papillomavirus Vaccine - Drug Profile 89
product Description 89
mechanism Of Action 89
r&d Progress 89
Human Papillomavirus Infections - Pipeline Review, H1 2014

4. rg-1-vlp - Drug Profile 90
product Description 90
mechanism Of Action 90
r&d Progress 90
hupaderm Vaccine - Drug Profile 91
product Description 91
mechanism Of Action 91
r&d Progress 91
subunit Vaccine For Human Papillomavirus Infections - Drug Profile 92
product Description 92
mechanism Of Action 92
r&d Progress 92
pl-202 - Drug Profile 93
product Description 93
mechanism Of Action 93
r&d Progress 93
nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 94
product Description 94
mechanism Of Action 94
r&d Progress 94
human Papilloma Virus Vaccine - Drug Profile 96
product Description 96
mechanism Of Action 96
r&d Progress 96
small Molecules For Bacterial And Viral Infections - Drug Profile 97
product Description 97
mechanism Of Action 97
r&d Progress 97
multivalent Vaccine Candidate For Human Papillomavirus Infections - Drug Profile 98
product Description 98
mechanism Of Action 98
r&d Progress 98
human Papilomavirus Vaccine - Drug Profile 99
product Description 99
mechanism Of Action 99
r&d Progress 99
small Molecules For Hpv Infections - Drug Profile 100
product Description 100
mechanism Of Action 100
r&d Progress 100
drug For Hpv - Drug Profile 102
product Description 102
mechanism Of Action 102
r&d Progress 102
therapeutic Hpv Vaccine - Drug Profile 103
product Description 103
mechanism Of Action 103
r&d Progress 103
second Generation Pentavalent Hpv Vaccine - Drug Profile 104
product Description 104
mechanism Of Action 104
r&d Progress 104
second Generation Trivalent Hpv Vaccine - Drug Profile 105
product Description 105
mechanism Of Action 105
r&d Progress 105
human Papillomavirus Infections - Recent Pipeline Updates 106
human Papillomavirus Infections - Dormant Projects 113
human Papillomavirus Infections - Discontinued Products 114
human Papillomavirus Infections - Product Development Milestones 115
featured News & Press Releases 115
feb 20, 2014: Fda Accepts For Review Mercks Biologics License Application For V503, Investigational 9-valent Human Papillomavirus Vaccine 115
nov 04, 2013: Mercks Investigational 9-valent Hpv Vaccine, V503, Prevented 97 Percent Of Cervical, Vaginal And Vulvar Pre-cancers Caused By Five
Additional Hpv Types, In Phase Iii Study 115
oct 24, 2013: Merck Provides Update On Investigational 9-valent Hpv Vaccine V503 To U.s. Advisory Committee On Immunization Practices 117
may 09, 2013: Gsk Announces New Commitment With Gavi Alliance To Supply Cervical Cancer Vaccine 117
may 09, 2013: Merck Receives Significant Portion Of Unicef Human Papillomavirus Vaccine Tender 118
apr 30, 2013: Immunogenicity Of Two Doses Of Merck's Hpv Vaccine May Be As Effective As Three, Study Finds 119
Human Papillomavirus Infections - Pipeline Review, H1 2014

5. dec 19, 2012: Sirnaomics Advances New Sirna Therapeutics Against Hpv Infection And Cervical Cancer 119
dec 06, 2012: New Studies Demonstrate Gardasil Has Long Duration Of Protection From Hpv Disease 120
oct 18, 2012: Genticel Announces Positive Data From Phase I Trial Of Procervix In Women Infected With High-risk Hpv Before Appearance Of Cervical
Lesions 121
oct 01, 2012: Kaiser Permanente Study Affirms Safety Of Hpv4 Vaccine For Adolescents And Young Women In Routine Clinical Care 122
appendix 123
methodology 123
coverage 123
secondary Research 123
primary Research 123
expert Panel Validation 123
contact Us 124
disclaimer 124
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Human Papillomavirus Infections - Pipeline Review, H1 2014